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Introduction
Currently, the diagnosis of Alzheimer's disease (AD) combines clinical criteria with biological markers reflecting the pathological changes in the brain (Dubois et al., 2014; McKhann et al., 2011) . Determination of biomarkers that can predict the clinical progression to AD is of utmost importance to accurately identify at-risk subjects for enrichment of disease-modifying treatment trials (Karran et al., 2011) . In particular, the amnestic subtype of mild cognitive impairment (aMCI) is associated with an increased risk of developing AD, corresponding to an annualized conversion rate of 30% (Rozzini et al., 2007; Schmidtke and Hermeneit, 2007) . In this respect, AD conversion prediction over a shorter time span, i.e. one or two years, can be considered clinically relevant, especially to identify rapid versus slow AD progressors.
The most accepted hypothetical model for the development of AD suggests a temporal order of the pathological changes in which amyloidosis triggers tau spreading outside of the medial temporal cortex, subsequently leading to the neurodegenerative processes and cognitive deterioration (Jack and Holtzman, 2013) . However, the causal role of amyloid in the aetiology of AD pathogenesis (amyloid cascade hypothesis) remains elusive and some argue for a tau-centric pathway or an interdependent role of amyloid and tau (Jack et al., 2016) . In 2018, the NIA-AA research framework 'A/T/N' was established which avoids the assumptions of the temporal ordering of the biomarkers . Herein, AD is defined as a continuous process in both cognitive and biomarker domains rather than as three separate clinical entities (i.e., preclinical, MCI, and dementia). The 'A+' in A/T/N refers to fibrillary Aβ deposition quantified as high retention on amyloid-PET or low Aβ1-42/Aβ1-40 levels in the cerebrospinal fluid (CSF) (Blennow et al., 2010; Herholz and Ebmeier, 2011) , 'T+' refers to tau pathology A C C E P T E D M A N U S C R I P T characterized by elevated CSF phosphorylated tau levels (P-tau181) or tau-PET uptake (Olsson et al., 2016; Villemagne et al., 2014) , and 'N+' reflects synaptic dysfunction and neuronal degeneration based on decreased 18 F-fluorodeoxyglucose ( 18 F-FDG) PET uptake, atrophy on magnetic resonance imaging (MRI) or elevated CSF total tau (T-tau) Knopman, 2012) . Thus, complete A/T/N characterization is possible using CSF or imaging biomarkers alone, as well as using a combination of both.
However, the disagreement between biomarker modalities within the different A/T/N categories may introduce bias when individual subjects are classified as positive or negative (Illán-Gala et al., 2018) . Moreover, these modalities (CSF/imaging) may not be fully interchangeable when predicting cognitive decline or MCI-to-AD conversion. Indeed, whereas amyloid-PET was found to be a predictor of future cognitive decline (Ben Bouallègue et al., 2017; Doraiswamy et al., 2014; Farrell et al., 2017; Landau et al., 2012) , CSF Aβ had a rather limited prognostic value (Ben Bouallègue et al., 2017; De Vos et al., 2016; Walhovd et al., 2010a) . Lastly, an extra level of variability may be introduced within one modality when using the CSF Aβ1-42/Aβ1-40 ratio instead of Aβ1-42 alone , or when selecting different reference regions for amyloid-PET standardized uptake value ratio (SUVR). For example, changes in 18 Fflorbetapir ( 18 F-AV45) SUVR normalized to a white matter reference region were shown to be better associated with changes in cognition compared to applying a cerebellar or pontine reference region (Chen et al., 2015) .
In contrast to the A+ and T+ biomarkers, the markers of neurodegeneration cannot be used to indicate Alzheimer's pathophysiologic processes as they are known to show topographical overlap with non-AD pathologies (Wirth et al., 2013) . However, structural and metabolic abnormalities correlate well with the symptom severity as they become present in closer proximity to the onset of cognitive decline A C C E P T E D M A N U S C R I P T (Chételat et al., 2005; Jack and Holtzman, 2013; Landau et al., 2012; Prestia et al., 2015; Storandt et al., 2009; Walhovd et al., 2010a; Yu et al., 2012) . Indeed previous literature have suggested their utility as predictors of short-term MCI-to-AD dementia conversion (Fellgiebel et al., 2007; Geroldi et al., 2006; Landau et al., 2010; Prestia et al., 2015; Visser et al., 2002; Yu et al., 2012) , although with limited interchangeability (Illán-Gala et al., 2018) .
Despite extensive literature on the associations between biomarkers and cognition, only few clinical trials and observational studies performed a complete A/T/N characterization of their participants included, using different biomarker modalities within the different categories (Dumurgier et al., 2017; Salloway et al., 2018; Wang et al., 2018) .
Therefore, in the present study, we aimed to investigate which A/T/N biomarkers (except for tau-PET) at baseline were associated with short-term cognitive decline in a population comprising the whole spectrum of AD, including cognitively healthy controls (HC), mild cognitive impairment (MCI), and AD dementia patients. Secondly, we determined which of the baseline biomarkers could discriminate MCI-to-AD dementia converters from nonconverters.
Materials and methods

Study population
Seventy-eight subjects were enrolled in the study, including 13 HC, 49 MCI and 16 AD dementia patients. They underwent 18 F-AV45 PET, 18 F-FDG PET, lumbar puncture, MRI, and an extensive neuropsychological examination at baseline. 18 F-AV45-PET and 18 F-FDG-PET were repeated after one year, whereas the cognitive battery was
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A C C E P T E D M A N U S C R I P T repeated after one and two years. The number of subjects per biomarker measure (both at baseline and follow-up) is listed in Table 1 . 
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Neuropsychological investigation
All patients underwent a neuropsychological examination, including the Mini-Mental State Examination (MMSE) and the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) which is composed of the immediate memory, delayed memory (subtests: word list recall, story recall, figure recall, word list recognition), language, attention, and visuospatialconstruction (figure copy and judgment of line orientation) index scores. The raw scores of the RBANS were converted to zscores based on the norm scores. These normative z-scores of the separate RBANS domains were dichotomized by using a -1.5 SD cut-off (no cognitive deficit versus cognitive deficit).
CSF biomarkers
CSF collection and processing methods are described elsewhere . CSF concentrations of Aβ1-42, Aβ1-40, T-tau, and P-tau181
were determined with commercially available single-analyte ELISA (INNOTEST® β-AMYLOID(1-42), β-AMYLOID(1-40), hTAU-Ag, and PHOSPHO-TAU(181P), respectively; Fujirebio Europe) as routinely performed in our lab (Somers et al., 2016) .
The laboratory technician performing the biomarker analyses was blinded to clinical diagnosis. In addition, the Aβ1-42/Aβ1-40, Aβ1-42/T-tau, and Aβ1-42/P-tau181 ratios were calculated. CSF biomarker results were not included in the consensus clinical diagnosis made by the panel.
Imaging biomarkers
Procedures for acquisition of PET and MRI images are described in . Baseline and follow-up PET scans were coregistered to baseline MRIs for each subject using PMOD v3.6 (PMOD Technologies Ltd., Zurich, Switzerland). Regions of interest were delineated based on brain parcellation of the anatomic MRIs using automated knowledge-based grey matter/white matter/CSF segmentation in PMOD. 18 F-FDG standardized uptake value ratios (SUVR) were derived from a static scan at 30-40 min post-injection and calculated in the precuneus and posterior cingulate cortex (PCC) target regions with a cerebellar gray matter reference region. Regional 18 F-AV45 SUVRs were derived at 50-60 min post-injection and normalized to either the cerebellar gray (SUVRCB) or the whole subcortical white matter (SUVRWM). A global cortical 18 F-AV45
SUVR was calculated as the volume-weighted average uptake in the frontal, temporal and parietal lobe. The longitudinal change in SUVR was computed as ΔSUVR=(SUVRFU-SUVRBL)/SUVRBL*100 (with BL: baseline; FU: follow-up) and therefore expressed as a percentage, enabling comparison between different reference regions despite their different scales. All data was corrected for partial volume effects based on the regionbased geometric transfer matrix method (GTM as described by (Rousset et al., 1998) ) and a 5x5x5mm PET scanner resolution.
MRI volumes, including hippocampal volume (HV), cortical grey matter volume (CGM), and white matter hyperintensity volume (WMH), were extracted by icometrix, using the CE-labelled and FDA-cleared software IcoBrain. The processing method is described elsewhere (Niemantsverdriet et al., 2018; Smeets et al., 2016) . All volumes were normalized to total head size.
Biomarker positivity
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All continuous biomarker values at baseline were also dichotomized as positive (i.e., suggestive for AD) or negative.
Two dichotomous measures of CSF status were generated, one based on the Aβ1-42/Aβ1-40 ratio and one based on the Aβ1-42/T-tau ratio. The CSF biomarker profile was considered to be positive if the Aβ1-42/Aβ1-40 value was below the cut-off (<0.067 pg/mL) or the Aβ1-42/T-tau value was below the cut-off (< 2.153 pg/mL). The cut-off values were in-house validated in autopsy-confirmed AD versus HC (Somers et al., 2016) .
18 F-FDG-PET biomarker positivity was defined using the automated quantitative analysis software MIMneuro (MIM Software Inc. Cleveland, OH), comparing each subject's scan on a voxel-by-voxel basis to a normal database comprising 43 HC. All images were normalized to the mean activity in the whole brain, pons, and cerebellum.
Two dichotomous measures of amyloid status were generated, one based on the visual PET reading and the other one using a quantitative cortical SUVR threshold. Both were described previously . The first measure used a database-assisted analysis in which the 18 F-AV45 uptake pattern of all subjects was compared to a normal pattern on a voxel-by-voxel basis allowing for calculation of zscores. The brain norm was created from a set of SUVR images acquired with Aβnegative HC (N = 9) and normalized to the CB. The second measure used a receiver operating characteristic (ROC) area under the curve (AUC) analysis using the SUVRCB and SUVRWM values of HC and AD dementia patients (cortical SUVRCB threshold = 1.203; SUVRWM threshold = 0.485).
MRI biomarker positivity was visually assessed by consensus of the clinical panel
and was based on the presence or absence of hippocampal atrophy using the axial T1 (Scheltens et al., 1992) .
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Statistical analysis
Statistical analyses were performed in IBM SPSS Statistics v24 and parameters were described as mean ± SD. Significance was determined at p < 0.05. Differences among diagnostic groups were assessed using χ 2 tests for categorical variables and
Kruskal-Wallis tests with Bonferroni correction for continuous variables. The difference in cortical 18 F-AV45 uptake between baseline and follow-up was tested using a Wilcoxon signed rank test.
Regression analyses
Associations between cognition and the other biomarkers at baseline were assessed for each biomarker separately, using general linear modeling corrected for the 
MCI-to-AD dementia conversion
compared using the AUC comparison function in JMP (JMP Pro v14, SAS Institute Inc., USA). Assumptions of the multiple variable models were met: 1) no collinearity between variables (e.g., three-variable model: variance inflation factor < 2, Pearson's r < 0.6), and 2) linear relationship between the variables and their log odds (Box-Tidwell test). For all analyses, the predictive power was evaluated through ROC analysis (probability cut-off = 50%). Sensitivity and specificity of the models were calculated. Sample sizes varied slightly between the different regression models due to missing data. Table 2 represents the demographic and biomarker data at baseline, grouped by clinical diagnosis. No differences between diagnostic groups were found in sex and APOE ε4 genotype. The MCI and AD dementia group showed significantly higher 18 F-AV45 and lower 18 F-FDG PET uptake, more cognitive impairment, and smaller HV compared to the HC group. Additionally, the AD dementia group showed significantly higher CSF T-tau, lower Aβ1-42/T-tau and Aβ1-42/P-tau181, as well as smaller CGM and more WMH compared to the HC group. Differences in CSF P-tau181 and Aβ1-42/Aβ1-40 between HC and AD dementia showed a trend towards statistical significance. The percentage of Aβ-PET+ subjects increased across diagnostic groups (31% HC, 80%
Results
Demographics
MCI, 100% AD dementia based on the cortical SUVRCB cut-off). Similarly, the percentage of CSF+ and MRI+ subjects also increased (CSF: 43% HC, 78% MCI, 93% AD dementia based on the Aβ1-42/Aβ1-40 cut-off, and 29% HC, 64% MCI, 93% AD dementia based on the Aβ1-42/T-tau cut-off; MRI: 15% HC, 71% MCI, 75% AD dementia based on visual reading).
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A C C E P T E D M A N U S C R I P T Significant associations are shown in bold typeface. All biomarkers that only showed nonsignificant associations were omitted from the Table. Abbreviations: CSF cerebrospinal fluid, HV hippocampal volume, MMSE Mini-Mental state examination, MRI magnetic resonance imaging, PCC posterior cingulate cortex,
PET positron emission tomography, P-tau181 phosphorylated tau181, SUVRCB standardized uptake value ratio normalized to cerebellar gray matter, SUVRWM standardized uptake value ratio normalized to subcortical white matter 
Influence of reference region selection for AV45 SUVR
When Aβ deposition was quantified as cortical SUVR referenced to WM, higher baseline SUVRWM was significantly associated with more cognitive decline over time (Δ delayed recall β = -0.40 (p = 0.029); Δ list recall β = -0.29 (p = 0.028); Δ story recall β = -0.28 (p = 0.020)), though none of the p-values survived FDR-correction. No associations were found for reference CB. The superior performance of WM normalization compared to CB normalization became also clear when 1-year changes in SUVR were investigated in a subset of our MCI and AD dementia patients with a follow-up PET scan (N = 23).
Firstly, global cortical 18 F-AV45 SUVRWM was significantly increased at 1-year follow-up compared to baseline (+2.61 ± 4% on average over all subjects, p = 0.015), in contrast to SUVRCB (+2.33 ± 9%, p = 0.412). Secondly, the number of subjects that showed a (contra-intuitively) SUVR decline over time (ΔSUVR < -0.5%) was smaller for reference WM compared to CB (17% versus 35% of the cases). Lastly, higher baseline 18 F-AV45
SUVRWM was significantly (p = 0.05) associated with smaller increases in SUVRWM (i.e., ΔSUVRWM) over time. This most likely indicates that amyloid accumulation slowed down in the clinical phase ( Supplementary Fig. 1 ). There was no such association for reference CB (p = 0.38).
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Influence of biomarker positivity on longitudinal cognitive changes
All biomarker positive groups (except CSF) at baseline showed significantly faster decline (time-by-status interaction) in MMSE and RBANS delayed memory index score over 2 years compared to their corresponding negative group (Table 5 and Fig. 1) .
The 18 F-FDG-and 18 F-AV45-positive group (based on visual reading) also showed a faster 1-year decline in MMSE and delayed memory index score, respectively, compared to the negative group. SUVRCB standardized uptake value ratio normalized to cerebellar gray matter, SUVRWM standardized uptake value ratio normalized to subcortical white matter
MCI-to-AD dementia conversion
Baseline characteristics of converters versus non-converters
Of the 42 MCI patients with a follow-up clinical diagnosis, 15 patients progressed to AD dementia at the time of the first follow-up (mean follow-up time was 415 ± 18 days), corresponding to an annual conversion rate of 31%. The groups of converters versus non-converters were not different with respect to age, sex, APOE ε4 genotype, education, 18 F-AV45-PET, and CSF levels. There was a significant difference in baseline MMSE (p = 0.023), RBANS delayed memory index score (p = 0.022), RBANS visuospatialconstruction index score (p = 0.007), HV (p < 0.0001), CGM volume (p = 0.002), and 18 F-FDG-PET in the precuneus (p < 0.0001) between both groups (Fig. 2) .
However, after FDR-correction, only HV, CGM, and 18 F-FDG-PET remained significant.
A C C E P T E D M
A N U S C R I P T HV was the strongest single variable based on its highest AUC of 0.89 (95% C.I.:
[0.80-0.99], sensitivity: 64%, specificity: 89%), and approximately 51.7% explained variance (Nagelkerke R 2 ) (Fig. 3A) . Addition of CGM or 18 F-FDG-PET to the singlevariable model of HV resulted in an AUC of 0.92 (95% C.I.: [0.83-1.00], sensitivity: 71%, specificity: 89%) and 0.91 (95% C.I.: [0.82-1.00], sensitivity: 86%, specificity: 92%), respectively (Fig. 3A) . However, the increases in AUC of the two-versus one-variable models were non-significant. The highest 2-variable AUC was reached for a combination of the RBANS visuospatialconstruction index score and either HV or 18 F-FDG-PET (Fig.   3B ). Their AUCs significantly increased (p = 0.023 and p = 0.030, resp.) compared to the one-variable model with visuospatialconstruction skills only. The combination of HV, 18 F-FDG-PET and visuospatialconstruction skills resulted in the strongest three-variable model with an AUC of 0.99 (95% C.I.: [0.96-1.00], sensitivity: 92%, specificity: 96%) ( Fig.   3B ). However, the increase in AUC compared to the two-variable models was nonsignificant. All significant one-, two-and three-variable(s) combinations are reported in Supplementary Table 1 , together with their AUC, accuracy, sensitivity and specificity. 
Discussion
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The current study investigated the utility of the 3 A/T/N biomarkers (A: CSF A and 18 F-AV45-PET; T: CSF P-tau181; N: CSF T-tau, MRI atrophy and 18 F-FDG-PET) with respect to concurrent cognitive function, cognitive decline and MCI-to-AD dementia conversion over 1 year. In line with literature (Chételat et al., 2005; Landau et al., 2012; Prestia et al., 2015; Storandt et al., 2009; Walhovd et al., 2010a; Yu et al., 2012) , we found that the neurodegenerative markers, including MRI-based HV and FDG-based hypometabolism in the posterior cingulate were most strongly associated with baseline cognition and short-term cognitive decline. Moreover, HV and 18 F-FDG-PET were the strongest single determinants of short-term conversion to AD dementia in the MCI group, corresponding to an accuracy of 80 and 83%, respectively. This is in line with accuracies of 66 to 83% that have been reported previously (Fellgiebel et al., 2007; Landau et al., 2010; Prestia et al., 2015; Visser et al., 2002; Yu et al., 2012) . The combination of 18 F-FDG-PET and HV resulted in an accuracy of 90% in our study. This implies that both imaging modalities are yielding complementary information when interpreted together (Walhovd et al., 2010b) . The AD-like patterns of 18 F-FDG hypometabolism and MRI atrophy develop according to a similar anatomic pattern and extent as the clinical features, explaining their direct relationship with cognition. However in clinical practice, it may be of greater interest to combine an imaging modality with a cognitive marker to predict conversion to AD dementia. Indeed, we found that the combination of a visuospatialconstruction score with either 18 F-FDG-PET or MRI HV significantly improved AUCs and resulted in a predictive accuracy of 89% and 86%, respectively. A combination of all three markers resulted in the highest accuracy of 94% (96% specificity, 92% sensitivity). Research on visuospatial abilities is relatively scarce even though it has shown significant potential for the detection of preclinical AD, as concluded by a recent review paper (Salimi et al., 2018) . Unlike memory deficits, visuospatial deficits rely on the
dysfunctioning of the parietal lobe, which is among the earliest manifestations of AD. The parietal lobe is involved in higher cognitive functions and highly vulnerable to metabolic impairment. Hence, cognitive testing for visuospatial functioning may be applied for differential diagnosis (discriminate AD dementia from non-AD dementias such as frontotemporal dementia) as well as for the prediction of MCI-to-AD dementia conversion.
In addition, it seems possible that different subtypes in prodromal AD are related to other cognitive areas, and thus show different patterns of cognitive decline (Kate et al., 2018) .
Visuospatial functioning is associated with two subtypes; the diffuse subtype in which cortical atrophy with intermediate clinical, cognitive and biological features are found, and also the subtype with pronounced parieto-occipital atrophy in combination with high CSF tau levels. On the other hand, combining MRI or 18 F-FDG-PET with either RBANS delayed memory index score or MMSE corresponded to diagnostic accuracies between 76 and 80%, however the sensitivity was relatively low in our study (57-71%).
Biomarkers related to the early events of the pathological cascade (referring to A+ of the A/T/N model) showed that higher baseline cortical 18 F-AV45 SUVRWM, notably in the parietal lobe and precuneus (data not shown), was associated with faster cognitive decline, irrespective of baseline clinical diagnosis. However, when all regression analyses were conducted separately in the Aβ+ group, we could not find significant associations between any of the biomarkers at baseline (except 18 F-FDG-PET) and cognitive decline (data not shown). These findings are in line with a previous study in a combined cohort of Aβ-and Aβ+ MCI patients (Doraiswamy et al., 2012) , indicating that the presence of Aβ deposits itself may be a more important predictor of cognitive decline than how much Aβ is present in the brain. Indeed, the extent and anatomical pattern of Aβ deposition are known to show poor correlations to cognitive severity or disease progression (Vandenberghe et al., 2013) . Therefore, the association between Aβ and
cognitive deficit is most likely of an indirect origin, in which abnormal Aβ accumulation triggers downstream neurodegenerative processes that, on their turn, exert direct effect on cognition. This might also explain why amyloid-PET was significantly associated with short-term cognitive decline in our whole cohort, but could not discriminate short-term MCI-to-AD dementia converters from non-converters. Due to small sample sizes, we could however not perform within-diagnostic group analyses to test this hypothesis.
The association between baseline 18 F-AV45 SUVR and ΔSUVR as well as Δcognition was only significant when a WM reference region was considered. Moreover, regional SUVRWM but not SUVRCB was significantly increased at follow-up in a subset of our clinical cohort, corresponding to +2-3% yearly. In contrast, Aβ deposition quantified by SUVRCB was (unexpectedly) decreased over time in 35% of the cases. In 4 out of the 8 subjects with longitudinal declining cortical SUVRCB, SUV was more increased in the reference region than in the target region, questioning the use of CB as a reference region for longitudinal purposes. Several recent studies have suggested the superior performance of a WM reference region for the 18 F-AV45 ligand, both in cross-sectional and longitudinal designs (Brendel et al., 2015; Chen et al., 2015; Landau et al., 2015; Ottoy et al., 2017; Shokouhi et al., 2016) . This could be related to its more favourable location in the same axial plane as the neocortical target areas (Blautzik et al., 2018) .
However, a recent 11 C-PiB study by (Lowe et al., 2018) found WM uptake to be dependent on age and cortical Aβ deposition, thereby questioning its validity as a reference region. In our study, WM SUVRCB changes were small (-0.1 ± 10 %), most likely because of the relatively advanced stage of our clinical cohort with high amyloid load at baseline and the short follow-up time (1 year).
Considered as neurodegenerative markers, CSF T-tau and Aβ1-42/T-tau were not associated with cognitive decline nor were they predictors of conversion in our study.
Previous studies found an association with cognitive decline (Ben Bouallègue et al., 2017; Dumurgier et al., 2017; Kester et al., 2009) or conversion (Bouwman et al., 2007; Mattsson et al., 2009; Vemuri et al., 2009; Vos et al., 2012) , whereas others did not (De Vos et al., 2016; Walhovd et al., 2010a) . In line with Vos et al. , we found only a weak correlation between the CSF Aβ1-42/T-tau and MRI-based HV markers of neuronal injury (data not shown). Vemuri et al. (Vemuri et al., 2009) reported that MRI could be closer related to disease progression than CSF T-tau as the latter may be more prone to diurnal physiologic variations, therefore reflecting transient rather than cumulative damage. In general, we could not find good relationships between any of the CSF markers and cognition at baseline. It appeared from our analysis that the prediction of cognition by CSF markers could be explained by the link with disease state, as CSF (in particular T-tau and P-tau markers) disappeared from the model after we additionally corrected for clinical diagnosis. In contrast, amyloid-PET/CSF, 18 F-FDG-PET, and HV retained an association with cognition even when diagnosis was considered. These findings were in line with the study by (Mattsson et al., 2017) . Cognitive function is, by clinical diagnostic definition, lower for subjects with MCI/AD than for controls. Therefore, in an attempt to attend this potential confound and investigate the independent and complementary information of a single biomarker on cognitive function and cognitive decline in a larger cohort, we corrected for baseline diagnosis. Models without clinical diagnosis as a covariate can be found in Supplementary Table 2 and 3. This study has a number of limitations. In our 1-year follow-up study, 15 out of 42 MCI patients (31%) converted to AD dementia, which is higher than the 8-16% expected annual risk of conversion (Landau et al., 2010; Mitchell and Shiri-Feshki, 2009 or A/T/N criteria). It is likely that for example CSF T-tau levels were associated with cognitive decline in the (non-converting) MCI subjects, but have reached a plateau in the late MCI/AD dementia phase. Thirdly, MCI subjects with clinical progression to unspecified dementias were included as it was not always possible to make the diagnosis of dementia due to AD solely on a clinical basis. A non-biomarker based diagnosis was performed in this study to avoid circular reasoning (i.e., the same tests are used to diagnose a disease and then to predict the diagnosis). However, the inclusion of unspecified dementia subjects may have decreased the predictive power of the biomarkers that were analyzed and may have increased the contribution of visuospatialconstruction score as a cognitive measure. Next, while we found that shortterm (1 year) prognosis of AD conversion relates strongly to neurodegenerative markers, we could not find such association for amyloid-PET or -CSF biomarkers. Based on earlier findings (Dickerson and Wolk, 2013) , it is likely that longer-term prognosis (> 2 years) in these individuals would be associated with a marker of amyloidosis. Lastly, 18 F-FDG SUVR was normalized to a cerebellar reference region, although pons normalization has been applied in most of the previous literature. In our study however, automatic segmentation processes tend to fail in reliably separating the pons from the whole brainstem, most likely because the posterior border of this region was not well delineated on MRI (Bauer et al., 2013) . Moreover, cerebellar normalization has been recommended for 18 F-FDG-PET by Bauer et al. (Bauer et al., 2013) as this region was least affected by
metabolic changes in AD. Lastly, the pons may be more susceptible to noise and thus longitudinal variability, owing to its small size and sensitivity to head motion.
Conclusions
Our results show that the neurodegenerative markers (MRI-based HV and 18 F-FDG-PET) were strongly associated to cognitive decline and short-term (1-year) MCI-to-AD dementia conversion. The use of a neurodegenerative marker in addition to a cognitive marker such as a visuospatialconstruction score could be applied in clinical practice to predict short-term conversion to AD dementia as well as for enrichment of disease-modifying treatment trials in MCI patients. CSF and amyloid-PET markers were not associated with short-term conversion. However, increased amyloid-PET uptake at baseline was associated with faster cognitive decline over time, only if SUVR was referenced to a WM reference region. 0.027 The two-variable models were constructed from making combinations between the significant single variables. The three-variable models were constructed from the addition of a third biomarker to the strongest two-variable models. The models were ordered in
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the table based on their AUC. χ 2 tests were used to determine significant improvement in the Log-likelihoods of the higher-compared to the lower-order models.
Abbreviations: Acc accuracy, AUC area under the curve, CGM cortical grey matter volume, Delayed RBANS delayed memory index score, HV hippocampal volume, MMSE Mini-Mental state examination, sens sensitivity, spec specificity, Visuo RBANS visuospatialconstruction index score
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A C C E P T E D M A N U S C R I P T Supplementary Table 2 . Associations of baseline cognition with other biomarkers ( 18 F-AV45-PET, 18 F-FDG-PET, MRI, CSF) at baseline, without correction for baseline clinical diagnosis.
Standardized regression coefficients β (and FDR-adjusted p-values) were retrieved from linear regression adjusted for age, sex, APOE ε4, and education. All biomarkers that showed non-significant associations were omitted from the Table. Abbreviations: Aβ amyloid-beta, CSF cerebrospinal fluid, HV hippocampal volume, MMSE Mini-Mental state examination, MRI magnetic resonance imaging, ns nonsignificant, PCC posterior cingulate cortex, PET positron emission tomography, P-tau181 phosphorylated tau181, SUVRCB standardized uptake value ratio normalized to cerebellar gray matter, SUVRWM standardized uptake value ratio normalized to subcortical white matter, T-tau total tau 
AV45 PET FDG PET MRI CSF
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A C C E P T E D M A N U S C R I P T Supplementary Table 3 . Associations of 1-year cognitive decline (Δ) with other biomarkers ( 18 F-FDG-PET, MRI) at baseline, without correction for baseline clinical diagnosis. Standardized regression coefficients β (and FDR-adjusted P-values) were retrieved from linear regression adjusted for age, sex, APOE ε4, education, baseline cognition, and cognition interval. All biomarkers that showed non-significant associations were omitted from the Table. Δcognition = ZFU -ZBL.
FDG PET MRI
Abbreviations: HV hippocampal volume, MMSE Mini-Mental state examination, MRI magnetic resonance imaging, ns non-significant, PCC posterior cingulate cortex, SUVR standardized uptake value ratio
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Highlights  FDG and MRI HV are the strongest predictors of cognitive decline and conversion to AD.
 Combination of visuospatialconstruction testing with FDG-PET or MRI HV present high predicting power of conversion.
 CSF and amyloid-PET seem less suitable as markers of disease progression.
 Increased AV45-PET predicts short-term cognitive decline if SUVR is referenced to WM instead of CB.
